Skip to main
ALGS
ALGS logo

Aligos Therapeutics (ALGS) Stock Forecast & Price Target

Aligos Therapeutics (ALGS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aligos Therapeutics is poised for a positive trajectory due to its evolving pipeline, particularly with ALG-055009, which has demonstrated significant liver fat reduction and beneficial lipid effects without the gastrointestinal liabilities of earlier therapies, thus enhancing its appeal for potential collaborators. Additionally, the company’s management highlights the substantial market potential of its programs, aimed at addressing major unmet medical needs, which could result in collaborative partnerships and multi-billion-dollar market opportunities. Furthermore, ALG-000184 has shown durable viral suppression in chronic hepatitis B treatment, reinforcing Aligos’s strong position within the biopharmaceutical landscape.

Bears say

Aligos Therapeutics faces significant clinical development risks, particularly regarding the safety and efficacy of its candidate ALG-000184, which could adversely impact future study outcomes. The company also grapples with regulatory uncertainties that may arise if authorities tighten approval criteria for its therapies or shift focus towards functional cures for chronic conditions. Furthermore, financing concerns loom as Aligos has a cash runway extending into the second half of 2026, coupled with the potential need for additional equity issuance to fund upcoming Phase 2b and Phase 3 studies.

Aligos Therapeutics (ALGS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aligos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aligos Therapeutics (ALGS) Forecast

Analysts have given Aligos Therapeutics (ALGS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aligos Therapeutics (ALGS) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aligos Therapeutics (ALGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.